R-CHOP VS CHOP IN DIFFUSE LARGE CELL AND FOLLICULAR LYMPHOMAS. EPIDEMIOLOGICAL DATA OF PATIENTS WITH LYMPHOMAS TREATED IN CARACAS (VENEZUELA) FOR 14 YEARS
(Abstract release date: 05/19/16)
EHA Library. Muller Soyano A. 06/09/16; 132535; E986
Disclosure(s): No relationship with corporate organization
Dr. Aixa Muller Soyano
Contributions
Contributions
Abstract
Abstract: E986
Type: Eposter Presentation
Background
Few epidemiological Venezuelan Lymphoma patients data are found in the literature to compare survival and the current standard treatment with chemoinmunotheraphy with Lymphoma patients from developed countries
Aims
The purpose of this paper is to present epidemiological data of patients with lymphoma treated by the Commission of lymphoma IOH and some private clinics in Caracas during the past 14 years and compare the efficacy of treatment of RCHOP vs CHOP
Methods
Materials and Methods A total of 1812 patients with lymphoma, of which 1214 were classified as non-Hodgkin lymphoma and 598 as Hodgkin's lymphoma were treated, and of these 1117 patients with lymphoma were studied from the pto epidemiologically between 1996- 2010 Lymphoma diagnosis was made based on clinical history, X-rays, CT, lymph and tissue biopsy (depending on the case), immunohistochemistry studies when required.
Results
Results Patients with lymphoma were classified into Hodgkin and non-Hodgkin 390 cases 827 casesHodgkin's lymphoma (HL) is subclassified in Nodular Sclerosis 62.6%, 27.7% mixed cellularity, lymphocyte-predominant 4.3% 5.4% Depletion LymphocyticThe age and sex of the patients were Nodular Sclerosis: 32.45 years (18-65), 129 female and 115 male, Mixed cellularity: 22.3 years (18-56), 37 female and 72 male, predominantly lymphocytic 22.6 years (18-67 ), 6 female and 11 male, depletion Lymphocytic 22 years (20-42) female and 15 maleThe stages were stage I: 5,5%, stage II: 44%, stage III: 31.1% stage IV: 19.4%.HL patients were treated with different chemotherapy protocols: MOPP, ABVD, STANDFORD V, HYBRID, COPP / ABVD, COPP / EBVD, BEACOPP and in some cases radiotherapyNon Hodgkin Lymphomas were subclassified by 36.4% Diffuse Large Cell, Follicular 24.1%, 10% Maltoma, 5.5% of peripheral blood cells, 3% mantle cell lymphoma, 20.8% other types of lymphoma such as mycosis Mycosis, immunoblastic Anaplastic, Lymphoblastic, Burkitt, Cutaneous B cell 45% of patients with follicular lymphoma had a high score FLIPI and 60% of diffuse large cell lymphoma had a high intermediate score with high-risk prognostic factors and only 15% of these were low-risk DLBCLNHL were treated with different protocols according to the year of admission and stage of CHOP disease, CHOP Bleo, MACOB B, ATT, Hyper-CVAD, CHOP MTX and from 2005 to 2010 55 patients were treated with R-CHOP and year 1999-2004 29 patients were treated with CHOP resulting overall survival in DLBCL with RCHOP 92.1% vs 67.9% and 89.5% LF vs 50%, event-free survival of 90% DLBCL with RCHOP CHOP vs 44% (p 0.002) and LF with CHOP vs 89.8 RCHOP age influenced patient survival (p 0.56). Other variables such as sex, type of lymphoma, stage had no impact on the EFS
Conclusion
Conclusion : 1117 patients with lymphoma were studied retrospectively. Patients were classified in 34.9 % and 65.1 % non -Hodgkin lymphoma. The most common subtype of LH was nodular sclerosis ( 62.57 %) and was more common in women and young adults of mixed cellularity HL was the second most common and the prevalence in lymphocytes and lymphocyte depletion constituted only 6.8 % and 8 7 %% the most common was the NHL diffuse large cell and the second Follicular NHL . The Venezuelan population is made up of a mixture of different indigenous races, Caucasian, Negroid, but it seems that this disease follows the same patterns reported in other populations Overall survival, event-free survival of DLBCL and LF was statistically significant in favor of RCHOP, which should be the treatment of choice in these pathologies
Session topic: E-poster
Type: Eposter Presentation
Background
Few epidemiological Venezuelan Lymphoma patients data are found in the literature to compare survival and the current standard treatment with chemoinmunotheraphy with Lymphoma patients from developed countries
Aims
The purpose of this paper is to present epidemiological data of patients with lymphoma treated by the Commission of lymphoma IOH and some private clinics in Caracas during the past 14 years and compare the efficacy of treatment of RCHOP vs CHOP
Methods
Materials and Methods A total of 1812 patients with lymphoma, of which 1214 were classified as non-Hodgkin lymphoma and 598 as Hodgkin's lymphoma were treated, and of these 1117 patients with lymphoma were studied from the pto epidemiologically between 1996- 2010 Lymphoma diagnosis was made based on clinical history, X-rays, CT, lymph and tissue biopsy (depending on the case), immunohistochemistry studies when required.
Results
Results Patients with lymphoma were classified into Hodgkin and non-Hodgkin 390 cases 827 casesHodgkin's lymphoma (HL) is subclassified in Nodular Sclerosis 62.6%, 27.7% mixed cellularity, lymphocyte-predominant 4.3% 5.4% Depletion LymphocyticThe age and sex of the patients were Nodular Sclerosis: 32.45 years (18-65), 129 female and 115 male, Mixed cellularity: 22.3 years (18-56), 37 female and 72 male, predominantly lymphocytic 22.6 years (18-67 ), 6 female and 11 male, depletion Lymphocytic 22 years (20-42) female and 15 maleThe stages were stage I: 5,5%, stage II: 44%, stage III: 31.1% stage IV: 19.4%.HL patients were treated with different chemotherapy protocols: MOPP, ABVD, STANDFORD V, HYBRID, COPP / ABVD, COPP / EBVD, BEACOPP and in some cases radiotherapyNon Hodgkin Lymphomas were subclassified by 36.4% Diffuse Large Cell, Follicular 24.1%, 10% Maltoma, 5.5% of peripheral blood cells, 3% mantle cell lymphoma, 20.8% other types of lymphoma such as mycosis Mycosis, immunoblastic Anaplastic, Lymphoblastic, Burkitt, Cutaneous B cell 45% of patients with follicular lymphoma had a high score FLIPI and 60% of diffuse large cell lymphoma had a high intermediate score with high-risk prognostic factors and only 15% of these were low-risk DLBCLNHL were treated with different protocols according to the year of admission and stage of CHOP disease, CHOP Bleo, MACOB B, ATT, Hyper-CVAD, CHOP MTX and from 2005 to 2010 55 patients were treated with R-CHOP and year 1999-2004 29 patients were treated with CHOP resulting overall survival in DLBCL with RCHOP 92.1% vs 67.9% and 89.5% LF vs 50%, event-free survival of 90% DLBCL with RCHOP CHOP vs 44% (p 0.002) and LF with CHOP vs 89.8 RCHOP age influenced patient survival (p 0.56). Other variables such as sex, type of lymphoma, stage had no impact on the EFS
Conclusion
Conclusion : 1117 patients with lymphoma were studied retrospectively. Patients were classified in 34.9 % and 65.1 % non -Hodgkin lymphoma. The most common subtype of LH was nodular sclerosis ( 62.57 %) and was more common in women and young adults of mixed cellularity HL was the second most common and the prevalence in lymphocytes and lymphocyte depletion constituted only 6.8 % and 8 7 %% the most common was the NHL diffuse large cell and the second Follicular NHL . The Venezuelan population is made up of a mixture of different indigenous races, Caucasian, Negroid, but it seems that this disease follows the same patterns reported in other populations Overall survival, event-free survival of DLBCL and LF was statistically significant in favor of RCHOP, which should be the treatment of choice in these pathologies
Session topic: E-poster
Abstract: E986
Type: Eposter Presentation
Background
Few epidemiological Venezuelan Lymphoma patients data are found in the literature to compare survival and the current standard treatment with chemoinmunotheraphy with Lymphoma patients from developed countries
Aims
The purpose of this paper is to present epidemiological data of patients with lymphoma treated by the Commission of lymphoma IOH and some private clinics in Caracas during the past 14 years and compare the efficacy of treatment of RCHOP vs CHOP
Methods
Materials and Methods A total of 1812 patients with lymphoma, of which 1214 were classified as non-Hodgkin lymphoma and 598 as Hodgkin's lymphoma were treated, and of these 1117 patients with lymphoma were studied from the pto epidemiologically between 1996- 2010 Lymphoma diagnosis was made based on clinical history, X-rays, CT, lymph and tissue biopsy (depending on the case), immunohistochemistry studies when required.
Results
Results Patients with lymphoma were classified into Hodgkin and non-Hodgkin 390 cases 827 casesHodgkin's lymphoma (HL) is subclassified in Nodular Sclerosis 62.6%, 27.7% mixed cellularity, lymphocyte-predominant 4.3% 5.4% Depletion LymphocyticThe age and sex of the patients were Nodular Sclerosis: 32.45 years (18-65), 129 female and 115 male, Mixed cellularity: 22.3 years (18-56), 37 female and 72 male, predominantly lymphocytic 22.6 years (18-67 ), 6 female and 11 male, depletion Lymphocytic 22 years (20-42) female and 15 maleThe stages were stage I: 5,5%, stage II: 44%, stage III: 31.1% stage IV: 19.4%.HL patients were treated with different chemotherapy protocols: MOPP, ABVD, STANDFORD V, HYBRID, COPP / ABVD, COPP / EBVD, BEACOPP and in some cases radiotherapyNon Hodgkin Lymphomas were subclassified by 36.4% Diffuse Large Cell, Follicular 24.1%, 10% Maltoma, 5.5% of peripheral blood cells, 3% mantle cell lymphoma, 20.8% other types of lymphoma such as mycosis Mycosis, immunoblastic Anaplastic, Lymphoblastic, Burkitt, Cutaneous B cell 45% of patients with follicular lymphoma had a high score FLIPI and 60% of diffuse large cell lymphoma had a high intermediate score with high-risk prognostic factors and only 15% of these were low-risk DLBCLNHL were treated with different protocols according to the year of admission and stage of CHOP disease, CHOP Bleo, MACOB B, ATT, Hyper-CVAD, CHOP MTX and from 2005 to 2010 55 patients were treated with R-CHOP and year 1999-2004 29 patients were treated with CHOP resulting overall survival in DLBCL with RCHOP 92.1% vs 67.9% and 89.5% LF vs 50%, event-free survival of 90% DLBCL with RCHOP CHOP vs 44% (p 0.002) and LF with CHOP vs 89.8 RCHOP age influenced patient survival (p 0.56). Other variables such as sex, type of lymphoma, stage had no impact on the EFS
Conclusion
Conclusion : 1117 patients with lymphoma were studied retrospectively. Patients were classified in 34.9 % and 65.1 % non -Hodgkin lymphoma. The most common subtype of LH was nodular sclerosis ( 62.57 %) and was more common in women and young adults of mixed cellularity HL was the second most common and the prevalence in lymphocytes and lymphocyte depletion constituted only 6.8 % and 8 7 %% the most common was the NHL diffuse large cell and the second Follicular NHL . The Venezuelan population is made up of a mixture of different indigenous races, Caucasian, Negroid, but it seems that this disease follows the same patterns reported in other populations Overall survival, event-free survival of DLBCL and LF was statistically significant in favor of RCHOP, which should be the treatment of choice in these pathologies
Session topic: E-poster
Type: Eposter Presentation
Background
Few epidemiological Venezuelan Lymphoma patients data are found in the literature to compare survival and the current standard treatment with chemoinmunotheraphy with Lymphoma patients from developed countries
Aims
The purpose of this paper is to present epidemiological data of patients with lymphoma treated by the Commission of lymphoma IOH and some private clinics in Caracas during the past 14 years and compare the efficacy of treatment of RCHOP vs CHOP
Methods
Materials and Methods A total of 1812 patients with lymphoma, of which 1214 were classified as non-Hodgkin lymphoma and 598 as Hodgkin's lymphoma were treated, and of these 1117 patients with lymphoma were studied from the pto epidemiologically between 1996- 2010 Lymphoma diagnosis was made based on clinical history, X-rays, CT, lymph and tissue biopsy (depending on the case), immunohistochemistry studies when required.
Results
Results Patients with lymphoma were classified into Hodgkin and non-Hodgkin 390 cases 827 casesHodgkin's lymphoma (HL) is subclassified in Nodular Sclerosis 62.6%, 27.7% mixed cellularity, lymphocyte-predominant 4.3% 5.4% Depletion LymphocyticThe age and sex of the patients were Nodular Sclerosis: 32.45 years (18-65), 129 female and 115 male, Mixed cellularity: 22.3 years (18-56), 37 female and 72 male, predominantly lymphocytic 22.6 years (18-67 ), 6 female and 11 male, depletion Lymphocytic 22 years (20-42) female and 15 maleThe stages were stage I: 5,5%, stage II: 44%, stage III: 31.1% stage IV: 19.4%.HL patients were treated with different chemotherapy protocols: MOPP, ABVD, STANDFORD V, HYBRID, COPP / ABVD, COPP / EBVD, BEACOPP and in some cases radiotherapyNon Hodgkin Lymphomas were subclassified by 36.4% Diffuse Large Cell, Follicular 24.1%, 10% Maltoma, 5.5% of peripheral blood cells, 3% mantle cell lymphoma, 20.8% other types of lymphoma such as mycosis Mycosis, immunoblastic Anaplastic, Lymphoblastic, Burkitt, Cutaneous B cell 45% of patients with follicular lymphoma had a high score FLIPI and 60% of diffuse large cell lymphoma had a high intermediate score with high-risk prognostic factors and only 15% of these were low-risk DLBCLNHL were treated with different protocols according to the year of admission and stage of CHOP disease, CHOP Bleo, MACOB B, ATT, Hyper-CVAD, CHOP MTX and from 2005 to 2010 55 patients were treated with R-CHOP and year 1999-2004 29 patients were treated with CHOP resulting overall survival in DLBCL with RCHOP 92.1% vs 67.9% and 89.5% LF vs 50%, event-free survival of 90% DLBCL with RCHOP CHOP vs 44% (p 0.002) and LF with CHOP vs 89.8 RCHOP age influenced patient survival (p 0.56). Other variables such as sex, type of lymphoma, stage had no impact on the EFS
Conclusion
Conclusion : 1117 patients with lymphoma were studied retrospectively. Patients were classified in 34.9 % and 65.1 % non -Hodgkin lymphoma. The most common subtype of LH was nodular sclerosis ( 62.57 %) and was more common in women and young adults of mixed cellularity HL was the second most common and the prevalence in lymphocytes and lymphocyte depletion constituted only 6.8 % and 8 7 %% the most common was the NHL diffuse large cell and the second Follicular NHL . The Venezuelan population is made up of a mixture of different indigenous races, Caucasian, Negroid, but it seems that this disease follows the same patterns reported in other populations Overall survival, event-free survival of DLBCL and LF was statistically significant in favor of RCHOP, which should be the treatment of choice in these pathologies
Session topic: E-poster
{{ help_message }}
{{filter}}